{"id":56247,"date":"2026-02-04T20:27:12","date_gmt":"2026-02-04T12:27:12","guid":{"rendered":"https:\/\/flcube.com\/?p=56247"},"modified":"2026-02-04T20:27:14","modified_gmt":"2026-02-04T12:27:14","slug":"datroway-tnbc-sbla-gets-fda-priority-review-for-triple-negative-breast-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56247","title":{"rendered":"Datroway TNBC sBLA Gets FDA Priority Review for Triple-Negative Breast Cancer"},"content":{"rendered":"\n<p><strong>AstraZeneca<\/strong> (AZ, <a href=\"https:\/\/www.google.com\/finance\/quote\/AZN:NYSE\">NASDAQ:\u202fAZN<\/a>) and <strong>Daiichi Sankyo<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/4568:TYO\">TYO:\u202f4568<\/a>) announced that the <strong>U.S. Food and Drug Administration (FDA)<\/strong> has accepted for review a <strong>supplemental Biologics License Application (sBLA)<\/strong> for <strong>Datroway (datopotamab deruxtecan)<\/strong> with <strong>priority review status<\/strong> for the treatment of adult patients with <strong>unresectable or metastatic triple\u2011negative breast cancer (TNBC)<\/strong> who are ineligible for PD\u20111\/PD\u2011L1 inhibitor therapy.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-sbla-details-amp-current-approvals\">sBLA Details &amp; Current Approvals<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Companies<\/strong><\/td><td>AstraZeneca \/ Daiichi Sankyo<\/td><\/tr><tr><td><strong>Drug<\/strong><\/td><td>Datroway (datopotamab deruxtecan)<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>TROP2\u2011targeting antibody\u2011drug conjugate (ADC)<\/td><\/tr><tr><td><strong>sBLA Indication<\/strong><\/td><td>Unresectable\/metastatic TNBC (PD\u20111\/PD\u2011L1 ineligible)<\/td><\/tr><tr><td><strong>Review Status<\/strong><\/td><td>FDA Priority Review<\/td><\/tr><tr><td><strong>Current Approvals<\/strong><\/td><td>\u2022 EGFR\u2011mutated locally advanced\/metastatic NSCLC (accelerated approval)<br>\u2022 HR\u2011positive, HER2\u2011negative metastatic breast cancer<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-commercial-outlook\">Market Impact &amp; Commercial Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>TNBC Market:<\/strong> US TNBC market valued at <strong>$1.5\u202fbillion<\/strong> : in 2025; represents <strong>~15%<\/strong> : of all breast cancers with limited treatment options for PD\u20111\/PD\u2011L1 ineligible patients<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> Competes with <strong>Gilead\u2019s Trodelvy<\/strong> (TROP2 ADC) and <strong>Keytruda<\/strong> combinations; Datroway\u2019s differentiated toxicity profile may offer advantage<\/li>\n\n\n\n<li><strong>Revenue Potential:<\/strong> Analysts estimate TNBC indication could add <strong>$400\u2013600\u202fmillion<\/strong> to Datroway\u2019s peak sales potential, which currently projects <strong>$2\u202fbillion<\/strong> : globally across all indications<\/li>\n\n\n\n<li><strong>Strategic Value:<\/strong> Priority review accelerates potential approval timeline; PDUFA date expected <strong>Q3\u202f2026<\/strong>; validates AZ\/Daiichi TROP2 platform beyond breast cancer<\/li>\n\n\n\n<li><strong>Unmet Need:<\/strong> PD\u20111\/PD\u2011L1 ineligible TNBC patients represent <strong>~30%<\/strong> : of metastatic population with no approved immunotherapy options<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding regulatory review timelines, commercial expectations, and revenue projections for Datroway. Actual results may differ due to FDA review outcomes, competitive dynamics, and market adoption rates.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>AstraZeneca (AZ, NASDAQ:\u202fAZN) and Daiichi Sankyo (TYO:\u202f4568) announced that the U.S. Food and Drug Administration&#8230;<\/p>\n","protected":false},"author":1,"featured_media":56248,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[35,130,16,194,38,871,978],"class_list":["post-56247","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-adc-xdc","tag-astrazeneca","tag-cancer","tag-daiichi-sankyo","tag-market-approval-filings","tag-nasdaq-azn","tag-tyo-4568"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Datroway TNBC sBLA Gets FDA Priority Review for Triple-Negative Breast Cancer - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"AstraZeneca (AZ, NASDAQ:\u202fAZN) and Daiichi Sankyo (TYO:\u202f4568) announced that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental Biologics License Application (sBLA) for Datroway (datopotamab deruxtecan) with priority review status for the treatment of adult patients with unresectable or metastatic triple\u2011negative breast cancer (TNBC) who are ineligible for PD\u20111\/PD\u2011L1 inhibitor therapy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=56247\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Datroway TNBC sBLA Gets FDA Priority Review for Triple-Negative Breast Cancer\" \/>\n<meta property=\"og:description\" content=\"AstraZeneca (AZ, NASDAQ:\u202fAZN) and Daiichi Sankyo (TYO:\u202f4568) announced that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental Biologics License Application (sBLA) for Datroway (datopotamab deruxtecan) with priority review status for the treatment of adult patients with unresectable or metastatic triple\u2011negative breast cancer (TNBC) who are ineligible for PD\u20111\/PD\u2011L1 inhibitor therapy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=56247\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-04T12:27:12+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-04T12:27:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0402.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56247#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56247\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Datroway TNBC sBLA Gets FDA Priority Review for Triple-Negative Breast Cancer\",\"datePublished\":\"2026-02-04T12:27:12+00:00\",\"dateModified\":\"2026-02-04T12:27:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56247\"},\"wordCount\":272,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56247#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0402.webp\",\"keywords\":[\"ADC \\\/ XDC\",\"AstraZeneca\",\"Cancer\",\"Daiichi Sankyo\",\"Market approval filings\",\"NASDAQ: AZN\",\"TYO: 4568\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56247#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56247\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=56247\",\"name\":\"Datroway TNBC sBLA Gets FDA Priority Review for Triple-Negative Breast Cancer - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56247#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56247#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0402.webp\",\"datePublished\":\"2026-02-04T12:27:12+00:00\",\"dateModified\":\"2026-02-04T12:27:14+00:00\",\"description\":\"AstraZeneca (AZ, NASDAQ:\u202fAZN) and Daiichi Sankyo (TYO:\u202f4568) announced that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental Biologics License Application (sBLA) for Datroway (datopotamab deruxtecan) with priority review status for the treatment of adult patients with unresectable or metastatic triple\u2011negative breast cancer (TNBC) who are ineligible for PD\u20111\\\/PD\u2011L1 inhibitor therapy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56247#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56247\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56247#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0402.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0402.webp\",\"width\":1080,\"height\":608,\"caption\":\"Datroway TNBC sBLA Gets FDA Priority Review for Triple-Negative Breast Cancer\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56247#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Datroway TNBC sBLA Gets FDA Priority Review for Triple-Negative Breast Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Datroway TNBC sBLA Gets FDA Priority Review for Triple-Negative Breast Cancer - Insight, China&#039;s Pharmaceutical Industry","description":"AstraZeneca (AZ, NASDAQ:\u202fAZN) and Daiichi Sankyo (TYO:\u202f4568) announced that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental Biologics License Application (sBLA) for Datroway (datopotamab deruxtecan) with priority review status for the treatment of adult patients with unresectable or metastatic triple\u2011negative breast cancer (TNBC) who are ineligible for PD\u20111\/PD\u2011L1 inhibitor therapy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=56247","og_locale":"en_US","og_type":"article","og_title":"Datroway TNBC sBLA Gets FDA Priority Review for Triple-Negative Breast Cancer","og_description":"AstraZeneca (AZ, NASDAQ:\u202fAZN) and Daiichi Sankyo (TYO:\u202f4568) announced that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental Biologics License Application (sBLA) for Datroway (datopotamab deruxtecan) with priority review status for the treatment of adult patients with unresectable or metastatic triple\u2011negative breast cancer (TNBC) who are ineligible for PD\u20111\/PD\u2011L1 inhibitor therapy.","og_url":"https:\/\/flcube.com\/?p=56247","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-04T12:27:12+00:00","article_modified_time":"2026-02-04T12:27:14+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0402.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=56247#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=56247"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Datroway TNBC sBLA Gets FDA Priority Review for Triple-Negative Breast Cancer","datePublished":"2026-02-04T12:27:12+00:00","dateModified":"2026-02-04T12:27:14+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=56247"},"wordCount":272,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=56247#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0402.webp","keywords":["ADC \/ XDC","AstraZeneca","Cancer","Daiichi Sankyo","Market approval filings","NASDAQ: AZN","TYO: 4568"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=56247#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=56247","url":"https:\/\/flcube.com\/?p=56247","name":"Datroway TNBC sBLA Gets FDA Priority Review for Triple-Negative Breast Cancer - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=56247#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=56247#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0402.webp","datePublished":"2026-02-04T12:27:12+00:00","dateModified":"2026-02-04T12:27:14+00:00","description":"AstraZeneca (AZ, NASDAQ:\u202fAZN) and Daiichi Sankyo (TYO:\u202f4568) announced that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental Biologics License Application (sBLA) for Datroway (datopotamab deruxtecan) with priority review status for the treatment of adult patients with unresectable or metastatic triple\u2011negative breast cancer (TNBC) who are ineligible for PD\u20111\/PD\u2011L1 inhibitor therapy.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=56247#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=56247"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=56247#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0402.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0402.webp","width":1080,"height":608,"caption":"Datroway TNBC sBLA Gets FDA Priority Review for Triple-Negative Breast Cancer"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=56247#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Datroway TNBC sBLA Gets FDA Priority Review for Triple-Negative Breast Cancer"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0402.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56247","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=56247"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56247\/revisions"}],"predecessor-version":[{"id":56249,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56247\/revisions\/56249"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/56248"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=56247"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=56247"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=56247"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}